Since its founding in 2008, Hemanext has envisioned a world with fewer and better transfusions. In its early years, multiple grants from the U.S. National Institutes of Health (NIH) enabled the company to demonstrate the feasibility of hypoxic RBC storage, develop its first prototype system and conduct in vivo research.
Recent Posts
- Hemanext Welcomes New Member to Board of Directors
- Hemanext Expands Board of Directors with Two New Members
- Hemanext Announces Close of Series B-2 Equity Funding Round
- Hemanext Inc. Announces First Patients Treated In A Clinical Trial Investigating the Efficacy of the Hemanext ONE® Red Blood Cell Processing and Storage System
- Hemanext signs agreement with Hemara Bio, a healthcare distributor in the U.A.E., to provide hospitals and clinicians across the GCC Region with Hemanext ONE® system